141 related articles for article (PubMed ID: 16280455)
21. The roles of amino acid residues at positions 216 and 219 in the structural stability and metabolic functions of rat cytochrome P450 2D1 and 2D2.
Narimatsu S; Kiryu K; Yonemoto R; Yoshino M; Kobatake M; Kazamori D; Hagino S; Masuda K; Katsu T; Asanuma M; Kumamoto T; Ishikawa T; Funae Y; Yamano S; Hanioka N; Naito S
Chem Biol Interact; 2008 Mar; 172(1):11-21. PubMed ID: 18191824
[TBL] [Abstract][Full Text] [Related]
22. Proposal of 5-methoxy-N-methyl-N-isopropyltryptamine consumption biomarkers through identification of in vivo metabolites from mice.
Fabregat-Safont D; Barneo-Muñoz M; Martinez-Garcia F; Sancho JV; Hernández F; Ibáñez M
J Chromatogr A; 2017 Jul; 1508():95-105. PubMed ID: 28602505
[TBL] [Abstract][Full Text] [Related]
23. 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter.
Sogawa C; Sogawa N; Tagawa J; Fujino A; Ohyama K; Asanuma M; Funada M; Kitayama S
Toxicol Lett; 2007 Apr; 170(1):75-82. PubMed ID: 17382495
[TBL] [Abstract][Full Text] [Related]
24. Analytical chemistry of synthetic routes to psychoactive tryptamines. Part I. Characterisation of the Speeter and Anthony synthetic route to 5-methoxy-N,N-diisopropyltryptamine using ESI-MS-MS and ESI-TOF-MS.
Brandt SD; Freeman S; Fleet IA; McGagh P; Alder JF
Analyst; 2004 Nov; 129(11):1047-57. PubMed ID: 15508033
[TBL] [Abstract][Full Text] [Related]
25. Prolonged delusional state triggered by repeated ingestion of aromatic liquid in a past 5-methoxy-N, N-diisopropyltryptamine abuser.
Fuse-Nagase Y; Nishikawa T
Addict Sci Clin Pract; 2013 Apr; 8(1):9. PubMed ID: 23577618
[TBL] [Abstract][Full Text] [Related]
26. Pharmaco-toxicological effects of the novel tryptamine hallucinogen 5-MeO-MiPT on motor, sensorimotor, physiological, and cardiorespiratory parameters in mice-from a human poisoning case to the preclinical evidence.
Bassi M; Bilel S; Tirri M; Corli G; Di Rosa F; Gregori A; Alkilany AM; Rachid O; Roda E; Zauli G; Locatelli CA; Marti M
Psychopharmacology (Berl); 2024 Mar; 241(3):489-511. PubMed ID: 38214743
[TBL] [Abstract][Full Text] [Related]
27. Metabolism of the designer drug α-pyrrolidinobutiophenone (α-PBP) in humans: identification and quantification of the phase I metabolites in urine.
Matsuta S; Shima N; Kamata H; Kakehashi H; Nakano S; Sasaki K; Kamata T; Nishioka H; Miki A; Katagi M; Zaitsu K; Sato T; Tsuchihashi H; Suzuki K
Forensic Sci Int; 2015 Apr; 249():181-8. PubMed ID: 25703013
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the separation of nine tryptamine standards based on gas chromatography, high performance liquid chromatography and capillary electrophoresis methods.
Wang MJ; Liu JT; Chen HM; Lin JJ; Lin CH
J Chromatogr A; 2008 Feb; 1181(1-2):131-6. PubMed ID: 18177659
[TBL] [Abstract][Full Text] [Related]
29. Metabolism of the recently encountered designer drug, methylone, in humans and rats.
Kamata HT; Shima N; Zaitsu K; Kamata T; Miki A; Nishikawa M; Katagi M; Tsuchihashi H
Xenobiotica; 2006 Aug; 36(8):709-23. PubMed ID: 16891251
[TBL] [Abstract][Full Text] [Related]
30. 5-methoxy-N,N-di(iso)propyltryptamine hydrochloride (Foxy)-induced cognitive deficits in rat after exposure in adolescence.
Compton DM; Dietrich KL; Selinger MC; Testa EK
Physiol Behav; 2011 May; 103(2):203-9. PubMed ID: 21295050
[TBL] [Abstract][Full Text] [Related]
31. Biotransformation of 5-methoxy-N-isopropyl-N-methyltryptamine by zebrafish and human liver microsome with high-resolution mass spectrometry.
Sen Zhao ; Wang Y; Zhong C; Chen J; Meng L
J Pharm Biomed Anal; 2024 Apr; 241():115987. PubMed ID: 38280235
[TBL] [Abstract][Full Text] [Related]
32. Abuse liability profile of three substituted tryptamines.
Gatch MB; Forster MJ; Janowsky A; Eshleman AJ
J Pharmacol Exp Ther; 2011 Jul; 338(1):280-9. PubMed ID: 21474568
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the developmental effects of 5-methoxy-N,N-diisopropyltryptamine (Foxy) to (+/-)-3,4-methylenedioxymethamphetamine (ecstasy) in rats.
Skelton MR; Schaefer TL; Herring NR; Grace CE; Vorhees CV; Williams MT
Psychopharmacology (Berl); 2009 Jun; 204(2):287-97. PubMed ID: 19198809
[TBL] [Abstract][Full Text] [Related]
34. Metabolism and toxicologic analysis of tryptamine-derived drugs of abuse.
Katagi M; Kamata T; Zaitsu K; Shima N; Kamata H; Nakanishi K; Nishioka H; Miki A; Tsuchihashi H
Ther Drug Monit; 2010 Jun; 32(3):328-31. PubMed ID: 20418800
[TBL] [Abstract][Full Text] [Related]
35. Effects of exposure to 5-MeO-DIPT during adolescence on brain neurotransmission and neurotoxicity in adult rats.
Noworyta-Sokołowska K; Kamińska K; Rzemieniec J; Wnuk A; Wojcieszak J; Górska AM; Kreiner G; Kajta M; Gołembiowska K
Forensic Toxicol; 2019; 37(1):45-58. PubMed ID: 30636982
[TBL] [Abstract][Full Text] [Related]
36. Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of "hallucinogenic designer drugs" in urine of consumers.
Pichini S; Pujadas M; Marchei E; Pellegrini M; Fiz J; Pacifici R; Zuccaro P; Farré M; de la Torre R
J Pharm Biomed Anal; 2008 Jun; 47(2):335-42. PubMed ID: 18262381
[TBL] [Abstract][Full Text] [Related]
37. Rhabdomyolysis after ingestion of "foxy," a hallucinogenic tryptamine derivative.
Alatrash G; Majhail NS; Pile JC
Mayo Clin Proc; 2006 Apr; 81(4):550-1. PubMed ID: 16610577
[TBL] [Abstract][Full Text] [Related]
38. An examination of the effects of 5-Methoxy-n, n-di(ISO)propyltryptamine hydrochloride (Foxy) on cognitive development in rats.
Compton DM; Selinger MC; Testa EK; Larkins KD
Psychol Rep; 2006 Jun; 98(3):651-61. PubMed ID: 16933659
[TBL] [Abstract][Full Text] [Related]
39. Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2003 Apr; 68(65):16427-30. PubMed ID: 12678045
[TBL] [Abstract][Full Text] [Related]
40. Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2004 Sep; 69(188):58950-3. PubMed ID: 15455477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
